To evaluate the Safety and efficacy of Raughan Ikseer for symptomatic relief in Wajaâ?? al-AsnÄ?n (Toothache)

Clinical Validation of a Unani Pharmacopoeial Formulation â?? Raughan Ikseer for symptomatic relief in Wajaâ?? al-AsnÄ?n (Toothache)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/02/005573

Enrollment

384

Registered

2015-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K050- Acute gingivitis Health Condition 2: null- Toothache

Interventions

Intervention1: Raughan Ikseer: Local application, twice daily for a period of seven days Control Intervention1: nil: NA

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex in the age group 18-65 years. • Patients having Wajaâ?? al-AsnÄ?n (Toothache) with or without any of the following symptoms: ï?§ Waram al-Lisa (Gingival swelling) ï?§ Humra al-Lisa (Gingival erythema) ï?§ Nazf al-Lisa (Gingival bleeding) ï?§ HassÄ?siyat HarÄ?riyya (Thermal sensitivity) â?? Pain triggered by Cold or Heat ï?§ SudÄ?â?? (Headache)

Exclusion criteria

Exclusion criteria: • Toothache does not respond to standard therapy. • Toothache accompanied by impaired neurological functions (loss of balance, weakness, numbness, or speech disturbances), double vision, seizures, mental disturbances, and loss of consciousness. • Toothache accompanied by persistent nausea, vomiting, fever and stiff neck. • Presence of a periodontal abscess as diagnosed from clinical examination of the painful tooth. • Presence of concomitant oral pain due to any other condition such as soft-tissue lesions (e.g., aphthous/ traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis) or multiple hard-tissue (e.g., carious) lesions; pain due to other surgical procedures, injuries or dental surface sensitivity. • Known cases of any other acute illness. • Known cases of severe Renal/ Hepatic/ Cardiac ailments. • Pregnant and lactating women. • History of Hypersensitivity to the study drug or any of its ingredients. • History of addiction (alcohol, drugs)

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Wajaâ?? al-AsnÄ?n (Toothache)Timepoint: 7 DAYS	—

Secondary

Measure	Time frame
Haematological and biochemical assessments for safety ï?· Improvement in the feeling of well-being of the patientTimepoint: 7 DAYS	—

Countries

India

Contacts

Public ContactDR PRADEEP KUMAR

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026